- Home
- LUNG vs IVVD Comparison
LUNG vs IVVD Comparison
Compare LUNG & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNG
- IVVD
- Stock Information
- Founded
- LUNG 1995
- IVVD 2020
- Country
- LUNG United States
- IVVD United States
- Employees
- LUNG N/A
- IVVD N/A
- Industry
- LUNG Industrial Specialties
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- LUNG Health Care
- IVVD Health Care
- Exchange
- LUNG Nasdaq
- IVVD Nasdaq
- Market Cap
- LUNG 65.6M
- IVVD 63.4M
- IPO Year
- LUNG 2020
- IVVD 2021
- Fundamental
- Price
- LUNG $1.55
- IVVD $1.15
- Analyst Decision
- LUNG Buy
- IVVD Strong Buy
- Analyst Count
- LUNG 7
- IVVD 4
- Target Price
- LUNG $7.66
- IVVD $3.64
- AVG Volume (30 Days)
- LUNG 480.4K
- IVVD 14.9M
- Earning Date
- LUNG 10-29-2025
- IVVD 11-13-2025
- Dividend Yield
- LUNG N/A
- IVVD N/A
- EPS Growth
- LUNG N/A
- IVVD N/A
- EPS
- LUNG N/A
- IVVD N/A
- Revenue
- LUNG $90,549,000.00
- IVVD $46,210,000.00
- Revenue This Year
- LUNG $10.30
- IVVD $112.35
- Revenue Next Year
- LUNG $14.72
- IVVD $272.14
- P/E Ratio
- LUNG N/A
- IVVD N/A
- Revenue Growth
- LUNG 18.24
- IVVD 1941.08
- 52 Week Low
- LUNG $1.47
- IVVD $0.35
- 52 Week High
- LUNG $9.37
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- LUNG 37.40
- IVVD 56.13
- Support Level
- LUNG $1.60
- IVVD $1.05
- Resistance Level
- LUNG $1.76
- IVVD $1.45
- Average True Range (ATR)
- LUNG 0.13
- IVVD 0.16
- MACD
- LUNG 0.02
- IVVD 0.01
- Stochastic Oscillator
- LUNG 2.86
- IVVD 47.37
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.